Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP
NCT06136585Phase 3Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sugammadex in neuromuscular block (NMB) (2 arms), sponsored by Cleveland Clinic. Primary endpoint: Time required from reversal of neuromuscular block to discharge readiness at 24 hours. Started Jun 2024; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on NCT06136585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136585.